Compare MGM Resorts International (MGM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Regeneron Pharmaceuticals Inc — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.9× MGM Resorts International's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| MGM | REGN | |
|---|---|---|
Market Cap | $11.86B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $812.27 |
52-Week Low | $30.72 | $545.46 |
Enterprise Value | $40.90B | $64.42B |
Dividend Yield | 0.03% | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
